AU2015340825B2 - Crystalline forms of ferric maltol - Google Patents

Crystalline forms of ferric maltol Download PDF

Info

Publication number
AU2015340825B2
AU2015340825B2 AU2015340825A AU2015340825A AU2015340825B2 AU 2015340825 B2 AU2015340825 B2 AU 2015340825B2 AU 2015340825 A AU2015340825 A AU 2015340825A AU 2015340825 A AU2015340825 A AU 2015340825A AU 2015340825 B2 AU2015340825 B2 AU 2015340825B2
Authority
AU
Australia
Prior art keywords
polymorph
degrees
theta
diffraction pattern
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015340825A
Other languages
English (en)
Other versions
AU2015340825A1 (en
Inventor
David Paul CHILDS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shield Tx UK Ltd
Original Assignee
Shield Tx UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52103522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015340825(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shield Tx UK Ltd filed Critical Shield Tx UK Ltd
Publication of AU2015340825A1 publication Critical patent/AU2015340825A1/en
Application granted granted Critical
Publication of AU2015340825B2 publication Critical patent/AU2015340825B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
AU2015340825A 2014-10-28 2015-10-23 Crystalline forms of ferric maltol Active AU2015340825B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1419174.6 2014-10-28
GB1419174.6A GB2531742B (en) 2014-10-28 2014-10-28 Polymorphs of ferric maltol
PCT/EP2015/074653 WO2016066555A1 (en) 2014-10-28 2015-10-23 Crystalline forms of ferric maltol

Publications (2)

Publication Number Publication Date
AU2015340825A1 AU2015340825A1 (en) 2016-08-25
AU2015340825B2 true AU2015340825B2 (en) 2016-11-24

Family

ID=52103522

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015340825A Active AU2015340825B2 (en) 2014-10-28 2015-10-23 Crystalline forms of ferric maltol

Country Status (18)

Country Link
US (1) US9802973B2 (enExample)
EP (1) EP3160951B1 (enExample)
JP (2) JP6404358B2 (enExample)
KR (1) KR102576930B1 (enExample)
CN (1) CN107001310B (enExample)
AU (1) AU2015340825B2 (enExample)
CA (1) CA2944210C (enExample)
CL (1) CL2017001030A1 (enExample)
EA (1) EA033323B1 (enExample)
ES (1) ES2661944T3 (enExample)
GB (1) GB2531742B (enExample)
IL (1) IL251863A0 (enExample)
MX (1) MX370730B (enExample)
PL (1) PL3160951T3 (enExample)
SA (1) SA517381406B1 (enExample)
SG (1) SG11201702639RA (enExample)
WO (1) WO2016066555A1 (enExample)
ZA (1) ZA201702136B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531742B (en) 2014-10-28 2016-10-05 Iron Therapeutics Holdings Ag Polymorphs of ferric maltol
CN112574158B (zh) * 2020-12-29 2022-08-02 南京百泽医药科技有限公司 一种麦芽酚铁晶型ii及其制备方法
IT202100018578A1 (it) 2021-07-14 2023-01-14 Indena Spa Dispersione amorfa di maltolo ferrico e relativo processo di preparazione
AU2022349859A1 (en) * 2021-09-21 2024-05-02 Apicore Pharmaceuticals Private Limited An improved process for the preparation of ferric maltol
CN119638661B (zh) * 2024-12-09 2025-11-14 金陵药业股份有限公司 一种麦芽酚铁-槲皮素共晶及其制备方法
CN119638662B (zh) * 2024-12-09 2025-11-14 金陵药业股份有限公司 一种麦芽酚铁-草酸共晶及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0159917A2 (en) * 1984-04-19 1985-10-30 National Research Development Corporation Pharmaceutical composition containing a hydroxypyrone-iron complex
WO2003097627A1 (en) * 2002-05-18 2003-11-27 Vitra Pharmaceuticals Limited Method of forming iron hydroxypyrone compounds
WO2012101442A1 (en) * 2011-01-27 2012-08-02 Iron Therapeutics Holdings Ag Process

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE37534E1 (en) 1982-10-22 2002-01-29 Btg International Limited Pharmaceutical compositions
GB2128998B (en) * 1982-10-22 1986-07-16 Nat Res Dev Pharmaceutical compositions of iron complexes of 3 hydroxy-4-pyrone
WO2014165607A2 (en) * 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
GB2531742B (en) 2014-10-28 2016-10-05 Iron Therapeutics Holdings Ag Polymorphs of ferric maltol

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0159917A2 (en) * 1984-04-19 1985-10-30 National Research Development Corporation Pharmaceutical composition containing a hydroxypyrone-iron complex
WO2003097627A1 (en) * 2002-05-18 2003-11-27 Vitra Pharmaceuticals Limited Method of forming iron hydroxypyrone compounds
WO2012101442A1 (en) * 2011-01-27 2012-08-02 Iron Therapeutics Holdings Ag Process

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Schlindwein, W. et al, Dalton Transactions, 2006, pp. 1313-1321 *

Also Published As

Publication number Publication date
WO2016066555A1 (en) 2016-05-06
CN107001310B (zh) 2020-05-22
CL2017001030A1 (es) 2018-01-19
IL251863A0 (en) 2017-06-29
MX370730B (es) 2019-12-20
EA201790667A1 (ru) 2017-08-31
BR112017008903A2 (pt) 2017-12-19
EP3160951A1 (en) 2017-05-03
CA2944210A1 (en) 2016-05-06
SA517381406B1 (ar) 2021-03-15
US9802973B2 (en) 2017-10-31
GB2531742B (en) 2016-10-05
US20170260222A1 (en) 2017-09-14
GB201419174D0 (en) 2014-12-10
SG11201702639RA (en) 2017-05-30
CA2944210C (en) 2017-06-20
ZA201702136B (en) 2018-11-28
EA033323B1 (ru) 2019-09-30
KR20170071446A (ko) 2017-06-23
JP6404358B2 (ja) 2018-10-10
GB2531742A (en) 2016-05-04
JP6678711B2 (ja) 2020-04-08
EP3160951B1 (en) 2017-12-06
MX2017005413A (es) 2017-10-04
PL3160951T3 (pl) 2018-07-31
CN107001310A (zh) 2017-08-01
AU2015340825A1 (en) 2016-08-25
ES2661944T3 (es) 2018-04-04
JP2018197268A (ja) 2018-12-13
KR102576930B1 (ko) 2023-09-12
JP2017535510A (ja) 2017-11-30

Similar Documents

Publication Publication Date Title
AU2015340825B2 (en) Crystalline forms of ferric maltol
JP6206689B2 (ja) ５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンナトリウム塩の結晶形ｉまたはｉｉを含有する医薬製剤
US12415825B2 (en) Manufacture of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] and compositions thereof
WO2015109445A1 (zh) 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
EP1364959B1 (en) Crystal of pyrimidine nucleoside derivative
HK1233619A1 (en) Crystalline forms of ferric maltol
HK1233619B (en) Crystalline forms of ferric maltol
BR112017008903B1 (pt) Formas cristalinas de maltol férrico
HK1223929B (zh) 5-氨基-2，3-二氢-(2，3-二氮杂萘)-1，4-二酮钠盐的晶型

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)